We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ahead of a massive consumer health spinoff, GlaxoSmithKline’s chairman search is over. The company Wednesday named ex-Novartis and AstraZeneca Chief Financial Officer Jonathan Symonds as its next chairman, effective Sept. 1.